Should I buy or sell Nemaura Medical stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nemaura Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NMRD shares. View NMRD analyst ratings or view top-rated stocks .

What is Nemaura Medical's stock price target for 2024?

1 equities research analysts have issued 12-month price objectives for Nemaura Medical's stock. Their NMRD share price targets range from $2.50 to $2.50. On average, they expect the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 2,872.7% from the stock's current price. View analysts price targets for NMRD or view top-rated stocks among Wall Street analysts .

How have NMRD shares performed in 2024?

Nemaura Medical's stock was trading at $0.2190 at the beginning of 2024. Since then, NMRD stock has decreased by 61.6% and is now trading at $0.0841. View the best growth stocks for 2024 here .

How were Nemaura Medical's earnings last quarter?

Nemaura Medical Inc. (NASDAQ:NMRD) announced its quarterly earnings data on Monday, February, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter.

How do I buy shares of Nemaura Medical?

Shares of NMRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NMRD

Nemaura Medical (NMRD) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free NMRD Stock Alerts

$0.08

+0.00 (+5.39%)

(As of 04:27 PM ET)

Compare

Today's Range: $0.07
▼
$0.09
50-Day Range: $0.07
▼
$0.10
52-Week Range: $0.07
▼
$1.25

Volume: 11,913 shs
Average Volume: 82,275 shs
Market Capitalization: $2.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.50

Get Nemaura Medical alerts:

Nemaura Medical MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,872.7% Upside
$2.50 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -0.97
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.70 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Nemaura Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Nemaura Medical has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for NMRD.

0.0

Dividend Strength

Dividend Yield
Nemaura Medical does not currently pay a dividend.
Dividend Growth
Nemaura Medical does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Nemaura Medical has received a 69.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Continuous glucose monitoring systems", "Continuous substance abuse monitoring systems", and "Continuous alcohol monitoring systems" products. See details.
Environmental Sustainability
The Environmental Impact score for Nemaura Medical is -0.97.

0.6

News and Social Media Coverage

Search Interest
1 people have searched for NMRD on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nemaura Medical insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.60% of the stock of Nemaura Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 4.41% of the stock of Nemaura Medical is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Nemaura Medical is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nemaura Medical is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Nemaura Medical Stock (NASDAQ:NMRD)

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

NMRD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NMRD Stock News Headlines

February 23, 2024 | benzinga.com

Nemaura Medical Stock (OTC:NMRD) Earnings Dates and Earning Calls

January 22, 2024 | finance.yahoo.com

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

January 3, 2024 | finanznachrichten.de

Nemaura Medical, Inc: Important Update on Listing Status and Strategic Direction

January 3, 2024 | finance.yahoo.com

Important Update on Listing Status and Strategic Direction

December 20, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Nemaura Medical on sugarBEAT Prospects and Market Expansion

December 13, 2023 | finanznachrichten.de

Nemaura Medical, Inc: Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

December 13, 2023 | finance.yahoo.com

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

November 27, 2023 | msn.com

Nemaura Medical (NMRD) Price Target Increased by 54.55% to 8.67

November 21, 2023 | finance.yahoo.com

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

November 17, 2023 | msn.com

Nemaura (NMRD) to Expand in UK With Metabolic Health Program

November 16, 2023 | finance.yahoo.com

Nemaura Medical First Half 2024 Earnings: US$0.13 loss per share (vs US$0.33 loss in 1H 2023)

November 15, 2023 | finanznachrichten.de

Nemaura Medical, Inc: Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

November 14, 2023 | seekingalpha.com

Acutus Medical Non-GAAP EPS of -$0.52, revenue of $5.2M

November 14, 2023 | finanznachrichten.de

Nemaura Medical, Inc: Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

November 14, 2023 | finance.yahoo.com

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs

November 13, 2023 | finance.yahoo.com

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update

October 18, 2023 | msn.com

SeaStar Medical gets FDA breakthrough status for cytokine storm device

September 26, 2023 | finance.yahoo.com

Nemaura Medical Announces Appointment of Mr Nikolai Rozanov as Strategic Adviser in Artificial Intelligence, to Assist in Development of its AI Health Coach, and Strengthen Outcomes in its CGM Based Metabolic and Type 2 Diabetes Programs.

September 18, 2023 | finance.yahoo.com

Nemaura Medical to Present at the Maxim Group Emerging Growth in A.I. Conference

September 16, 2023 | seekingalpha.com

Nemaura Medical says compliance regain with Nasdaq rules not expected

September 14, 2023 | finanznachrichten.de

Nemaura Medical, Inc: Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

September 14, 2023 | finance.yahoo.com

Nemaura Medical Provides Update on Nasdaq Compliance Status and Process

September 14, 2023 | benzinga.com

Top Penny Stock Gainers Momentum Watchlist (ORHB, GSAC, NMRD, SASI)

September 13, 2023 | finance.yahoo.com

Nemaura Medical Announces Interim Results from its Collaboration with the UK’s National Health Service on its Metabolic Health & Weight Loss Program

September 12, 2023 | finance.yahoo.com

Nemaura Medical Announces Participation at HLTH 2023, Las Vegas

See More Headlines

Receive NMRD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nemaura Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/12/2024
Today: 4/19/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:NMRD
CUSIP: N/A
CIK: 1602078
Web: nemauramedical.com
Phone: (646) 416-8000
Fax: N/A
Employees: 36
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $2.50
High Stock Price Target: $2.50
Low Stock Price Target: $2.50
Potential Upside/Downside: +2,872.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,140,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -142.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.19
Quick Ratio: 0.03

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 30.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.41) per share
Price / Book: -0.21

Miscellaneous

Outstanding Shares: 28,900,000
Free Float: 16,877,000
Market Cap: $2.43 million
Optionable: Optionable
Beta: -0.06

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Dewan Fazlul Hoque Chowdhury Ph.D. (Age 51)
Chairman, Interim CFO, CEO, President and Principal Financial & Accounting Officer
Comp: $338.58k
Dr. Arash Ghadar (Age 47)
Chief Operating Officer
Mr. Jay L. Warner
Head of U.S. Commercial Operations
Mr. Thomas Bendix Mortensen
Head of E.U. Commercial Operations & Marketing
Ms. Samantha Sanders
Global Head of Digital Programs

Key Competitors

View All Competitors

Insiders

Arash Ghadar-Ghadr
Bought 100,000 shares on 1/5/2024
Total: $14,000.00 ($0.14/share)

View All Insider Transactions

NMRD Stock Analysis - Frequently Asked Questions

Should I buy or sell Nemaura Medical stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nemaura Medical in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NMRD shares.
View NMRD analyst ratings or view top-rated stocks.
What is Nemaura Medical's stock price target for 2024?: 1 equities research analysts have issued 12-month price objectives for Nemaura Medical's stock. Their NMRD share price targets range from $2.50 to $2.50. On average, they expect the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 2,872.7% from the stock's current price.
View analysts price targets for NMRD or view top-rated stocks among Wall Street analysts.
How have NMRD shares performed in 2024?: Nemaura Medical's stock was trading at $0.2190 at the beginning of 2024. Since then, NMRD stock has decreased by 61.6% and is now trading at $0.0841.
View the best growth stocks for 2024 here.

How were Nemaura Medical's earnings last quarter?: Nemaura Medical Inc. (NASDAQ:NMRD) announced its quarterly earnings data on Monday, February, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter.
How do I buy shares of Nemaura Medical?: Shares of NMRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NMRD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nemaura Medical (NMRD) Stock Price, News & Analysis

Nemaura Medical MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Nemaura Medical Stock (NASDAQ:NMRD)

NMRD Stock Price History

NMRD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

NMRD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™